Kadmon (NYSE:KDMN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Sunday, AnalystRatings.com reports. They currently have a $25.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 383.56% from the company’s current price.

A number of other equities analysts also recently commented on KDMN. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Thursday, June 4th. Raymond James initiated coverage on Kadmon in a report on Tuesday, May 19th. They set an “outperform” rating and a $7.00 target price for the company. Oppenheimer restated a “buy” rating and set a $8.00 target price on shares of Kadmon in a report on Thursday, May 7th. Finally, ValuEngine upgraded Kadmon from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Seven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $10.88.

Shares of KDMN stock opened at $5.17 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.40 and a current ratio of 6.42. Kadmon has a fifty-two week low of $1.98 and a fifty-two week high of $5.50. The stock has a 50 day moving average price of $4.63 and a two-hundred day moving average price of $4.43. The company has a market capitalization of $844.96 million, a P/E ratio of -7.39 and a beta of 1.47.

Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%. The company had revenue of $6.74 million during the quarter, compared to the consensus estimate of $0.38 million. As a group, equities analysts predict that Kadmon will post -0.61 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC bought a new position in shares of Kadmon in the first quarter worth about $53,000. Windsor Creek Advisors LLC purchased a new position in Kadmon during the 1st quarter valued at approximately $60,000. Meeder Asset Management Inc. grew its holdings in Kadmon by 49.1% during the 4th quarter. Meeder Asset Management Inc. now owns 14,843 shares of the company’s stock valued at $68,000 after buying an additional 4,888 shares in the last quarter. JS Capital Management LLC purchased a new position in Kadmon during the 1st quarter valued at approximately $65,000. Finally, Raymond James & Associates purchased a new position in Kadmon during the 1st quarter valued at approximately $73,000. 85.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Recommended Story: What is the definition of market timing?

Analyst Recommendations for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.